Chronic conditions | |||
Number of diagnoses (total) | Median (IQR) | Min | Max |
 3143 | 5 (4 – 6) | 1 | 14 |
Most frequent diagnoses | n patients | % of participating patients | |
 Hypertension | 490 | 84.6% | |
 Arthrosis | 266 | 45.9% | |
 Diabetes mellitus II | 220 | 38.0% | |
 Dyslipidaemia | 202 | 34.9% | |
 Atrial fibrillation | 179 | 30.9% | |
 Coronary heart disease | 175 | 30.2% | |
 Osteoporosis | 157 | 27.1% | |
 Depression | 124 | 21.4% | |
 Benign prostatic hypertrophy | 110 | 19.0% | |
 Gastro-oesophageal reflux disease | 98 | 16.9% | |
 Chronic heart failure | 93 | 16.1% | |
 Chronic obstructive pulmonary disease (COPD) | 81 | 14.0% | |
 Chronic renal failure | 73 | 12.6% | |
 Hyperuricaemia / gout | 65 | 11.2% | |
 Hypothyroidism | 64 | 11.1% | |
 Insomnia | 60 | 10.4% | |
 Cerebrovascular disease / dementia | 58 (54 + 4) | 10.0% (9.3% + 0.7%) | |
Drug use | |||
Number of drugs (total) | Median (IQR) | Min | Max |
 5614 | 9 (8 – 11) | 8 | 20 |
Number of drugs per patient | n patients | % of participating patients | |
 8 – 9 drugs | 330 | 57.0% | |
 ≥ 10 drugs | 249 | 43.0% | |
Most frequently used drug classes per patienta | n patients | % of participating patients | |
 ARBs + ACE-inhibitors | 481 (251 + 230) | 83.1% (43.4% + 39.7%) | |
 PPIs | 320 | 55.3% | |
 Statins | 319 | 55.1% | |
 Platelet-aggregation inhibitors | 311 | 53.7% | |
 Beta-blockers | 306 | 52.8% | |
 Minor diuretics (predominantly hydrochlorothiazide) | 273 | 47.2% | |
 CCBs | 248 | 42.8% | |
 Loop diuretics (predominantly Furosemide) | 244 | 42.1% | |
 Vitamins (predominantly vit. D) | 227 | 39.2% | |
 Antidepressants + antipsychotics | 215 | 37.1% | |
 Oral anticoagulants | 190 | 32.8% | |
 Anxiolytics/hypnotics (Benzodiazepines + Zolpidem) | 173 | 29.9% | |
 Dietary supplements (predominantly Calcium) | 171 | 29.5% | |
 Oral antidiabetic drugs | 156 | 26.9% | |
 Antiasthmatic agents incl. Beta-adrenergics + anticholinergics | 134 | 23.1% | |
 Opioids | 127 | 21.9% | |
 Analgesics - Paracetamol | 126 | 21.8% | |
 Thyroid hormones | 114 | 19.7% | |
 Corticosteroids | 106 | 18.3% | |
 NSAIDs + COX-2-inhibitors (Coxibe) | 88 | 15.2% |